Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15 [cited 2022 Dec 26];140(11):1229–53. Available from: https://ashpublications.org/blood/article/140/11/1229/485458/The-International-Consensus-Classification-of.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022 36:7. 2022 Jun 22 [cited 2022 Dec 26];36(7):1720–48. Available from: https://www.nature.com/articles/s41375-022-01620-2.

Longo DL, Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, editor. https://doi.org/10.1056/NEJMra2027612. 2021 Mar 3 [cited 2022 Apr 1];384(9):842–58. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra2027612.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23 [cited 2019 Oct 18];116(12):2040–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20548096.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct [cited 2019 Oct 18];12(11):1013–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21940214.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New England Journal of Medicine. 1995 Dec 7 [cited 2020 Sep 23];333(23):1540–5. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199512073332305.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 2017 Dec 28 [cited 2020 Jul 26];377(26):2531–44. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1707447.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 2019 Jan 3 [cited 2020 Jul 26];380(1):45–56. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1804980.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020 Sep 19 [cited 2021 Mar 17];396(10254):839–52. Available from: http://www.thelancet.com/article/S0140673620313660/fulltext.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.

Article  CAS  PubMed  Google Scholar 

Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–8. https://doi.org/10.1182/blood.2019002729. ([cited 2023 Dec 24]).

Article  CAS  PubMed  Google Scholar 

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. New England Journal of Medicine. 2022 Jan 27 [cited 2022 Apr 1];386(4):351–63. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2115304

Alizadeh AA, Elsen MB, Davis RE, Ma CL, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

Article  CAS  PubMed  Google Scholar 

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherng HJJ, Westin J. Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2021 Jan 6;1–17. Available from: https://www.tandfonline.com/doi/abs/10.1080/10428194.2020.1869228.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

Article  CAS  PubMed  Google Scholar 

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.e14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang MC, Tian S, Fu D, Chen SJ, Xu PP, Zhao WL. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41:1705-1716.e5. https://doi.org/10.1016/j.ccell.2023.09.004. ([cited 2023 Dec 24]).

Article  CAS  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014 [cited 2020 Sep 27]. p. 3059–67. Available from: /pmc/articles/PMC4979083/?report=abstract.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2010 Apr 10 [cited 2020 Sep 27];28(11):1896–903. Available from: https://pubmed.ncbi.nlm.nih.gov/20212248/.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024–34.

Article  PubMed  Google Scholar 

Le Gouill S, Casasnovas RO. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver? Blood. 2017 Jun 8 [cited 2022 Sep 23];129(23):3059–70. Available from: https://ashpublications.org/blood/article/129/23/3059/36036/Interim-PET-driven-strategy-in-de-novo-diffuse.

El-Galaly TC, Jakobsen LH, Hutchings M, De Nully Brown P, Nilsson-Ehle H, Szekely E, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol. 2015 Dec 1 [cited 2023 Dec 24];33(34):3993–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26438115/.

Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, et al. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021;5(5):1283–90. https://doi.org/10.1182/bloodadvances.2020002690. ([cited 2023 Dec 24]).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cescon DW, Bratman S V., Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer 2020 1:3. 2020 Mar 20 [cited 2023 Dec 24];1(3):276–90. Available from: https://www.nature.com/articles/s43018-020-0043-5.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells 1. Cancer Res. 2001 [cited 2023 Dec 27];61:1659–65. Available from: http://aacrjournals.org/cancerres/article-pdf/61/4/1659/3252577/ch040101659p.pdf.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36(16):1631–41.

Article  CAS  PubMed  Google Scholar 

Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Annals of Oncology. 2009 Aug 1 [cited 2023 Dec 27];20(8):1408–13. Available from: http://www.annalsofoncology.org/article/S0923753419409575/fulltext.

Kurtz DM, Green MR, Bratman S V., Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015 Jun 11 [cited 2020 Jul 26];125(24):3679–87. Available from: https://pubmed.ncbi.nlm.nih.gov/25887775/.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep [cited 2023 Dec 27];14(9):985–90. Available from: https://pubmed.ncbi.nlm.nih.gov/18670422/.

Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015 [cited 2020 Jul 26];16(5):541–9. Available from: https://pubmed.ncbi.nlm.nih.gov/25842160/.

Ching T, Duncan ME, Newman-Eerkes T, McWhorter MME, Tracy JM, Steen MS, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020 Jun 30 [cited 2023 Dec 27];20(1):1–15. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07077-9.

Newman AM, Bratman S V., To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine 2014 20:5. 2014 Apr 6 [cited 2022 May 7];20(5):548–54. Available from: https://www.nature.com/articles/nm.3519.

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016 Nov 9 [cited 2020 Jul 26];8(364):364ra155–364ra155. Available from: https://stm.sciencemag.org/content/8/364/364ra155.

Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017 Apr 6 [cited 2020 Aug 10];129(14):1947–57. Available from: https://ashpublications.org/blood/article-pdf/129/14/1947/1399720/blood719641.pdf.

Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018 Aug 1 [cited 2023 Dec 31];8(8). Available from: https://pubmed.ncbi.nlm.nih.gov/30069017/.

Le Goff E, Blanc-Durand P, Roulin L, Lafont C, Loyaux R, MBoumbae DL, et al. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. Br J Haematol. 2023 Jul 1 [cited 2023 Dec 22];202(1):54–64. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18809.

Samorodnitsky E, Jewell BM, Hagopian R, Miya J, Wing MR, Lyon E, et al. Evaluation of hybridization capture versus amplicon‐based methods for whole‐exome sequencing. Hum Mutat. 2015 Sep 1 [cited 2023 Dec 31];36(9):903. Available from: /pmc/articles/PMC4832303/.

Stokowski RP, Tabari E, Bogard P, Hacker C, Kameneva OK, Ji T, et al. Detection of early molecular response (EMR) and minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using a validated next generation sequencing (NGS) assay for the detection of tumor variants in circulating tumor (ct)DNA. Blood. 2022;140(Supplement 1):9257–8. https://doi.org/10.1182/blood-2022-162814. ([cited 2023 Dec 27]).

Article  Google Scholar 

Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology 2016 34:5. 2016 Mar 28 [cited 2022 Nov 26];34(5):547–55. Available from: https://www.nature.com/articles/nbt.3520.

•• Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology 2021 39:12. 2021 Jul 22 [cited 2022 Apr 2];39(12):1537–47. Available from: https://www.nature.com/articles/s41587-021-00981-w. This pivotal study established the viability of sequencing phased variants as an ultrasensitive method of detecting ctDNA and MRD in B-cell lymphomas but also solid tumors. PhasED-seq potentially is the most sensitive ctDNA assay in development in DLBCL.

Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine 2020 26:7. 2020 Jun 1 [cited 2023 Dec 30];26(7):1114–24. Available from: https://www.nature.com/articles/s41591-020-0915-3.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications 2017 8:1. 2017 Nov 6 [cited 2021 Dec 3];8(1):1–13. Available from: https://www.nature.com/articles/s41467-017-00965-y.

Raman L, van der Linden M, de Vriendt C, van den Broeck B, Muylle K, Deeren D, et al. Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. Haematologica. 2022 Jan 1 [cited 2023 Dec 30];107(1):211–20. Available from: https://pubmed.ncbi.nlm.nih.gov/33299235/.

Cherng HJJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 Aug 4 [cited 2022 Sep 24];140(5):504–15. Available from: https://ashpublications.org/blood/article/140/5/504/485178/Risk-assessment-with-low-pass-whole-genome.

Narkhede MS, Tomassetti S, Iqbal M, Tin A, Rivero-Hinojosa S, George GV, et al. Role of circulating tumor DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma. Blood. 2023;142(Supplement 1):4376–4376. https://doi.org/10.1182/blood-2023-186603. ([cited 2023 Dec 30]).

Article  Google Scholar 

Merryman RW, Rhoades J, Xiong K, Antel K, An HH, Redd RA, et al. A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL. Blood. 2023;142(Supplement 1):527–527. https://doi.org/10.1182/blood-2023-189962. ([cited 2023 Dec 30]).

Article  Google Scholar 

Figaredo G, Martín-Muñoz A, Barrio S, Parrilla L, Campos-Martín Y, Poza M, et al. Genetic profiling of cell-free DNA in liquid biopsies: a complementary tool for the diagnosis of B-cell lymphomas and the surveillance of measurable residual disease. Cancers (Basel). 2023 Aug 1 [cited 2023 Dec 30];15(16). Available from: https://pubmed.ncbi.nlm.nih.gov/37627050/.

Rivas-Delgado A, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clinical Cancer Research. 2021;27(2):513–21. https://doi.org/10.1158/1078-0432.CCR-20-2558. ([cited 2023 Dec 31]).

Article  CAS  PubMed  Google Scholar 

•• Meriranta L, Alkodsi A, Pasanen A, Lepistö M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139(12):1863–77. https://doi.org/10.1182/blood.2021012852. This is a comprehensive study using hybrid capture sequencing that covered the breadth of applications of ctDNA in DLBCL, including pre-treatment prognostication, liquid genotyping at baseline and relapse, assessment of molecular response, and detection of MRD.

Article  CAS  PubMed  Google Scholar 

Cherng HJJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, et al. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023;7(7):1137–45. https://doi.org/10.1182/bloodadvances.2022008174. ([cited 2023 Jun 26]).

Article  CAS  PubMed  Google Scholar 

Jardin F, Raghavan V, Tracy S, Balasubramanian S, Sehn LH, Flowers CR, et al. Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: results from the POLARIX study. Blood. 2023;142(Supplement 1):169–169. https://doi.org/10.1182/blood-2023-178564. ([cited 2024 Jan 2]).

Article  Google Scholar 

Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell lymphoma. Clinical Cancer Research. 2016 Aug 1 [cited 2022 May 1];22(15):3801–9. Available from: https://aacrjournals.org/clincancerres/article/22/15/3801/79298/Molecular-Profile-and-FDG-PET-CT-Total-Metabolic.

Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020 Mar 24 [cited 2022 May 1];4(6):1082–92. Available from: https://ashpublications.org/bloodadvances/article/4/6/1082/452720/SAKK38-07-study-integration-of-baseline-metabolic.

Mikhaeel NG, Heymans MW, Eertink JJ, De Vet HCW, Boellaard R, Dührsen U, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol. 2022 [cited 2024 Jan 2];40(21):2352–60. Available from: https://pubmed.ncbi.nlm.nih.gov/35357901/.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2018 Oct 1 [cited 2020 Jul 26];36(28):2845–53. Available from: https://pubmed.ncbi.nlm.nih.gov/30125215/.

• Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2021;39(23):2605–16. This study strongly correlated ctDNA quantity with other markers of tumor burden as well as diagnosis-to-treatment interval, which is an important surrogate for the urgency of treatment initiation with many implic